India's dominance in global capability centres is evolving. These hubs are now integrated, managing complex functions beyond support. Risin...

The shift reflects a structural change in how multinationals use their India operations, moving beyond cost-focused support roles to centre...

Global firms are bringing more work in-house at their India centres. Artificial intelligence is boosting productivity. This reduces relianc...

Novo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to...

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The...

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development of ⁠the therap...

Novo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...

Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...

Eli Lilly Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on A...

Global demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

The Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cance...

Novo Nordisk shares jumped 10% on Tuesday after the U.S. Food ⁠and Drug Administration approved its weight-loss pill, giving the Danish dru...

Sun Pharmaceutical Industries Ltd announced that its Baska manufacturing facility has been classified as Official Action Indicated (OAI) by...

European shares dipped to a two-week low on Wednesday, mirroring global investor nervousness over elevated equity valuations. Technology st...

AstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...